key: cord-0806690-4xgndb8y authors: Peeters, M.; Verbruggen, L.; Teuwen, L.; Vanhoutte, G.; Kerckhove, S. Vande; Peeters, B.; Raats, S.; Van der Massen, I.; De Keersmaecker, S.; Debie, Y.; Huizing, M.; Pannus, P.; Neven, K.; Ariën, K.K.; Martens, G.A.; Van Den Bulcke, M.; Roelant, E.; Desombere, I.; Anguille, S.; Goossens, M.; Vandamme, T.; van Dam, P. title: REDUCED HUMORAL IMMUNE RESPONSE AFTER BNT162B2 COVID-19 MRNA VACCINATION IN CANCER PATIENTS UNDER ANTI-NEOPLASTIC TREATMENT date: 2021-09-08 journal: ESMO Open DOI: 10.1016/j.esmoop.2021.100274 sha: 29c424c99d6ac2368e062bc5202d2064480470e4 doc_id: 806690 cord_uid: 4xgndb8y BACKGROUND: Cancer patients are at higher risk of developing severe COVID-19. However, safety and efficacy of COVID-19 vaccination in cancer patients undergoing treatment is unclear. PATIENTS AND METHODS: In this interventional prospective multi-cohort study, priming and booster doses of the BNT162b2 COVID-19 vaccine were administered 21 days apart to solid tumor patients receiving chemotherapy, immunotherapy, targeted- or hormonal therapy, and patients with a hematologic malignancy receiving rituximab or after allogeneic hematopoietic stem cell transplantation. Vaccine safety and efficacy (until three months post-booster) were assessed. Anti-SARS-CoV-2 receptor binding domain (RBD) antibody levels were followed over time (until 28 days post-booster) and in vitro SARS-CoV-2 50% neutralization titers (NT50) towards the wild-type Wuhan strain were analyzed 28 days post-booster. RESULTS: Local and systemic adverse events (AEs) were mostly mild to moderate (only 1-3% of patients experiencing severe AEs). Local, but not systemic, AEs occurred more frequently after booster dose. 28 days post-booster vaccination of 197 cancer patients, RBD-binding antibody titers and NT50 were lower in the chemotherapy group (234.05IU/mL [95%CI 122.10-448.66] and NT50 of 24.54 [95% CI 14.50-41.52]) compared to healthy individuals (1844.93IU/mL [95% CI 1383.57-2460.14] and NT50 of 122.63 [95% CI 76.85-195.67]), irrespective of timing of vaccination during chemotherapy cycles. Extremely low antibody responses were seen in hematology patients receiving rituximab, only two patients had RBD-binding antibody titers necessary for 50% protection against symptomatic SARS-CoV-2 infection (<200IU/mL) and only one had NT50 above the limit of detection. During the study period, five cancer patients tested positive for SARS-CoV-2 infection, including a case of severe COVID-19 in a patient receiving rituximab, resulting in a 2-week hospital admission. CONCLUSION: The BNT162b2 vaccine is well-tolerated in cancer patients under active treatment. However, the antibody response of immunized cancer patients was delayed and diminished, mainly in patients receiving chemotherapy or rituximab, resulting in breakthrough infections. app. In addition, all patients attending the oncology day care unit, were screened for SARS-162 CoV-2 using PCR on mouth and oropharyngeal rinse samples before their treatment and in 163 Belgium testing is required for people returning from travel abroad, persons that were in close 164 contact with an infected person, or with suggestive symptoms such as fever or acute 165 respiratory illness. For all patients, this data was monitored up unit three months post-166 booster dose. 167 The primary endpoint was IgG antibody level to SARS-CoV-2 RBD antigen at 28 days post- All analyses were performed with the use of an intention-to-treat principle. As prespecified 175 in the statistical analysis plan, geometric means of the SARS-CoV-2 RBD-IgG titer at 28 days 176 post-booster vaccination was compared using an analysis of variance between treatment 177 cohorts with pairwise-comparison using Tukey's honestly significant difference (HSD) post hoc 178 test. Robustness of results was confirmed using non-parametric testing with Kruskal-Wallis 179 test between treatment cohorts with pairwise-comparison using Dunn's post hoc test. As an 180 exploratory analysis, a linear regression mode for outcome at day 28 post-booster 181 vaccination, and linear mixed-effects model over time was fitted to log-transformed IgG 182 measurements. Proportions of high-responding and low-responding subjects at day 28 post-183 booster were compared by Fisher exact testing. In addition, high-responding and low-184 responding cancer patients were compared using a logistic model for outcome at day 28. 185 Exploratory analysis in treatment sub-cohorts was performed using similar statistical 186 techniques. A two-sided p-value of <0·05 after Holm-Bonferroni correction for multiple 187 testing was considered statistically significant (Further details: see Supplementary Appendix 188 J o u r n a l P r e -p r o o f 8 and protocol). Spearman correlation was calculated between IgG antibody level to SARS-CoV-189 2 RBD and S1 antigen per timepoint for all cancer patients and between IgG antibody level to 190 SARS-CoV-2 RBD at 28 days post-booster and NT50 titers at this timepoint. nine patients (4·6%) received a delayed booster dose due to active infection or cancer 202 treatment-related complications ( Figure 1 ). All subjects in the healthy control cohort received 203 both priming and booster doses exactly 21 days apart. 204 The most frequently reported local AE was mild-to-moderate pain at the injection site. Severe 206 reactogenicity occurred in 1% of the patients following priming dose and in 3% of the patients 207 following booster dose ( Figure 2A ). The percentage of patients reporting localized pain and 208 redness was higher following booster dose (21·5% versus 9%; 10·2% versus 3% respectively; 209 Figure 2A ). For patients receiving targeted/hormonal therapy, the proportion reporting a local 210 AEs was higher after booster than after priming dose (32·5% versus 516·3% , Figure 2B ), while 211 no significant differences were observed in other cohorts. All local AEs resolved within 3 to 5 212 The reported systemic AEs were similar after each dose, with fatigue (13% after 214 priming dose, 17·5% after booster dose) and muscle/joint pain (15·5% after priming dose and 215 9 17% after booster dose) being the most common ( Figure 2C ). Severe systemic AEs were 216 reported in less than 2% after either dose (fatigue in 0·5% and muscle/joint pain in 1%; Figure 217 2C). The proportion of patients suffering from systemic AEs after either of the vaccine 218 administrations was similar across all study cohorts ( Figure 2D ). 219 Seven serious AEs were reported. One patient with stage IV breast cancer under oral 220 capecitabine treatment had a non-fatal pulmonary embolism. As it is well-known that the risk 221 of thromboembolic events is higher among cancer patients, 21 this was considered as cancer-222 and not vaccine-related by the investigators. Two patients had transient mild neurological 223 complaints (5-6 days after vaccine administration) which disappeared within 48 hours, with 224 normal brain magnetic resonance imaging and no evidence for thrombotic or immunologic 225 etiology. Four patients died during the study period. Three cancer-related deaths were 226 considered unrelated to the BNT162b2 vaccine. One patient died due to myocardial 227 infarction. This patients had a history of atrial fibrillation (under treatment with bisopropol), 228 which in combination with the presence of an infection provoked the myocardial infarction. 229 However, we cannot complete rule out that this event was vaccine-related. 230 The geometric mean titer (GMT) of SARS-CoV-2 RBD-IgG antibodies 28 days post-booster in 232 patients with solid tumors receiving chemotherapy was significantly lower than the healthy 233 controls (GMT respectively 2955·04 IU/mL [95% CI 2280·17-3829·65] and 234·05 IU/mL [95% 234 cohorts could be categorized as high-responding, when considering the pre-defined cut-off of 243 200 IU/mL (100% control cohort; 95% targeted/hormonal therapy cohort). The proportion 244 high-responders among the immunotherapy cohort was 80%, similar to healthy controls. 245 Moreover, no difference could be seen between patients receiving immunotherapy with or 246 without chemotherapy. However, the percentage of high-responders in the chemotherapy 247 and hematology cohort (respectively 55% and 29%) was significantly lower compared to the 248 healthy controls high-responders ( Figure Fifteen cancer patients (7·5%) and six healthy controls (15%) already had SARS-CoV-2 RBD-261 IgG titers above LLQ before priming doses, indicating a previous SARS-CoV-2 infection, but 262 only four cancer patients and none of the healthy controls reported PCR-confirmed COVID-263 19 before the start of the study. Excluding patients with baseline IgG titers above LLQ yielded 264 comparable results for primary outcome (see Supplementary Appendix). 265 The vaccine induced humoral immune response was assessed more in depth by analyzing the 266 anti S1 antibody response and the in vitro 50% neutralization titers (NT50) towards the wild-267 type Wuhan SARS-CoV-2 strain. Results on the anti S1 antibody response highly correlated BNT162b2 or mRNA-1273 26 . As seen in the latter study, also in our study some of these 337 patients mount no or very low levels (e.g. below the lower limit of detection) of (neutralizing) 338 antibodies. In our study, adapting the timing of vaccination relative to the chemotherapy 339 administration did not affect the vaccine-induced immune response. Although in 340 contradiction with recommendations for vaccine administration between chemotherapy 341 cycles 32 , this is in line with non-mRNA vaccines such as influenza 33 compered to asymptomatic infection. 39 It has indeed been demonstrated that while the 357 effectiveness towards hospitalization after priming dose is almost as high as after booster 358 dose (74% and 87%), for the protection against symptomatic disease, the effectiveness 359 increases steeply after booster dose ( 57% compared to 94%). 40 It should be noted that the 360 patient showing severe symptoms did not show seroconversion 28 days post-booster, most 361 probably due to the rituximab treatment at the moment of vaccination, which is known to 362 affect antibody production. In this study, the immune response after a COVID-19 vaccine in a cancer population under 379 treatment is monitored. In contrast to preliminary findings in cancer patients, where the main 380 difference between healthy controls and patients was the failure to produce any response, 381 rather than the magnitude of the response 25 , a substantial proportion of our patients has 382 seroconversion (e.g. a IgG level above the LLQ) without reaching levels necessary for 50% 383 protection against symptomatic SARS-CoV-2 infection (<200 IU/mL). Moreover, even though 384 it is widely accepted that SARS-CoV-2 RBD-IgG antibodies correlate with neutralizing antibody 385 capacity 14 and this is indeed the case for the overall study population, we here identified a 386 subgroup of participants showing seroconversion without neutralization capacity against the 387 wild type strain. This phenomenon was seen in subjects from all subgroups, including the 388 healthy controls, and already described in a small cohort of donors of convalescent plasma, 389 where donors with similar NT50 values of 240 had different IgG ELISA titers of 5 400 and 16 390 200. 44 Speculation on this subject points towards the presence of epitopes on RBD that do 391 not result in in vitro receptor binding or the presence of the "original antigenic sin" 392 phenomenon in which previous exposure to common coronaviruses might lead to an early 393 and high-titer immune response after SARS-CoV-2 infection-or in this case vaccination-that 394 uses memory instead of naïve B cells as such producing IgG that may not be neutralizing. 45 395 However, as we here see this phenomenon more frequently in cancer patients, including over 396 half of the patients receiving chemo-or immunotherapy and those with a hematological 397 malignancy (24/49, 7/15 and 8/14 respectively), it is tempting to speculate that anti-398 neoplastic treatment during vaccination might lead to the formation of dysfunctional 399 antibodies. As this is fully speculative at the moment, further research in this context is 400 needed. 401 The strength of this study is that we specifically investigate RBD antibodies rather than spike 403 protein antibodies as cross-reactivity with other coronavirus subtypes has been reported. 46 404 Moreover, in contrast to the previous studies in this context we combine both anti-RBD IgG 405 levels with in vitro neutralizing capacity to have a more in depth representation of the 406 humoral immune response. Furthermore, we report a long-term follow up of the antibody 407 response up unit 28 days (4 weeks) after booster dose. Despite all this, we acknowledge the 408 lack data on cellular immunity for these patients to be able to fully examinate the vaccine 409 induced immune response. 410 This study demonstrates that although the BNT162b2 COVID-19 vaccine is well-tolerated in 412 cancer patients under active treatment, including patients under immunotherapy, some 413 cancer patients lack the capacity to mount an efficient immune response, especially patients 414 receiving chemotherapy or rituximab treatment and irrespective of the timing of vaccine 415 administration. As such, group immunity and self-protection is of paramount importance in 416 these cases and caregivers, household members and/or close contacts of these patients 417 (adults regardless of age) should be vaccinated as early as possible. 47 In addition, this study 418 raises the question for third dose vaccination to boost immunity in cancer patients, as this 419 has recently been shown to significantly improve the immunogenicity of the BNT162b2 420 vaccine. 48 421 In conclusion, BNT162b2 vaccine administration is safe in cancer patients under anti-423 neoplastic treatment, but the reduced SARS-CoV-2 RBD-IgG antibody levels indicate a 424 Remdesivir in adults with severe COVID-19: a 505 randomised, double-blind, placebo-controlled, multicentre trial Dexamethasone in Hospitalized Patients with 507 Covid-19 The false promise of herd immunity for COVID-19 Seroconversion in patients with cancer and 511 oncology health care workers infected by SARS-CoV-2 Immunoglobin G/total antibody testing for 518 SARS-CoV-2: A prospective cohort study of ambulatory patients and health care workers in 519 two Belgian oncology units comparing three commercial tests COVID-19 in Cancer Patients, Risk 522 Factors for Disease and Adverse Outcome, a Population-Based Study From Norway Factors associated with COVID-19-525 related death using OpenSAFELY COVID-19) severity and mortality among solid cancer patients and impact of the disease on 528 anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19) Analyses of Risk, Racial Disparity, and Outcomes 531 SARS-CoV-2 and cancer: Are they really 533 partners in crime? Safety and Efficacy of the BNT162b2 mRNA 535 Covid-19 Vaccine Vaccination of oncology patients: an effective tool and 537 an opportunity not to be missed Anti-infective vaccination strategies in 539 patients with hematologic malignancies or solid tumors-Guideline of the Infectious Diseases 540 Working Party (AGIHO) of the German Society for Hematology and Medical Oncology 541 (DGHO) Vaccinations in patients with hematological malignancies Clinical validation of the Siemens quantitative 545 SARS-CoV-2 spike IgG assay (sCOVG) reveals improved sensitivity and a good correlation 546 with virus neutralization titers The tele-transition of toxicity 548 management in routine oncology care during the severe acute respiratory syndrome CoV-2) pandemic Prescreening for COVID-19 in patients 551 receiving cancer treatment using a patient-reported outcome platform Thromboembolic events in cancer 554 patients on active treatment with cisplatin-based chemotherapy: another look Efficacy of the influenza vaccine in patients 557 with malignant lymphoma Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing 560 Treatment for Cancer Immunogenicity of the BNT162b2 562 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological 563 malignancies in Lithuania: a national prospective cohort study Safety and immunogenicity of one versus 566 two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of 567 a prospective observational study Immunogenicity of SARS-CoV-2 messenger 569 RNA vaccines in patients with cancer Fifth-week immunogenicity and safety of 571 anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and 572 myeloproliferative malignancies on active treatment: preliminary data from a single 573 institution Efficacy of the BNT162b2 mRNA COVID-19 575 Vaccine in Patients with Chronic Lymphocytic Leukemia Response to first vaccination against SARS-577 CoV-2 in patients with multiple myeloma Immunogenicity and safety of the influenza A 579 H1N1v 2009 vaccine in cancer patients treated with cytotoxic chemotherapy and/or targeted 580 therapy: the VACANCE study Toxicity of adjuvant endocrine 582 therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis Timing isn't everything: Influenza vaccination in cancer 585 patients Optimal timing of influenza vaccination during 3-587 week cytotoxic chemotherapy cycles Immunogenicity and Optimal Timing of 13-Valent 589 Pneumococcal Conjugate Vaccination during Adjuvant Chemotherapy in Gastric and 590 Colorectal Cancer: A Randomized Controlled Trial PARP inhibition and immune modulation: scientific 592 rationale and perspectives for the treatment of gynecologic cancers Effect of rituximab on human in vivo 595 antibody immune responses Selective effects of cyclophosphamide 597 therapy on activation, proliferation, and differentiation of human B cells Immunosuppressive effect of 600 cyclophosphamide on white blood cells and lymphocyte subpopulations from peripheral 601 blood of Balb/c mice Impact and effectiveness of mRNA 603 BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, 604 and deaths following a nationwide vaccination campaign in Israel: an observational study 605 using national surveillance data BNT162b2 mRNA Covid-19 Vaccine in a 607 Nationwide Mass Vaccination Setting Influenza vaccination of cancer patients 610 during PD-1 blockade induces serological protection but may raise the risk for immune-611 related adverse events Vaccination and Immune Checkpoint 613 Inhibitors: Does Vaccination Increase the Risk of Immune-related Adverse Events? A 614 Systematic Review of Literature Short-term safety of the 616 BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune 617 checkpoint inhibitors Treatment of 5 Critically Ill Patients With COVID-19 619 With Convalescent Plasma COVID-19: are neutralizing antibodies neutralizing enough? 621 Transfusion (Paris) 2020 Common Human Coronaviruses and SARS-CoV-2 Using Coronavirus Antigen Microarray. 624 bioRxiv : the preprint server for biology 2020 COVID-19 vaccine guidance for patients with 626 cancer participating in oncology clinical trials Three Doses of an 628 mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients. The New England journal of 629 medicine